TUESDAY, OCTOBER 24, 2017 |
| Welcome, Introductions & Goals by Program Chairs |
| Session I
|
| from Virology Education on Vimeo. State of the ART: Integrase Inhibitors Resistance Charles Boucher, MD, PhD Erasmus Medical Center, Rotterdam, The Netherlands
|
| State of the ART: Integrase Inhibitors (clinical overview) (not yet available) Jonathan Schapiro, MD Sheba Medical Center, Ramat Gan, Israel
|
| Session II
|
| from Virology Education on Vimeo. What is the virological support for reduced drug regimens? Anne-Geneviève Marcelin, PharmD, PhD Pitié Salpêtrière Hospital, Paris, France
|
| What is the clinical support for reduced drug regimens? (not available) David Cooper, MD, DSc University of New South Wales, Sydney, Australia |
| 
Can we use HIV reservoir assays to predict VF in simplification strategies? (not available) Linos Vandekerckhove, MD, PhD Ghent University Hospital, Ghent, Belgium |
| Session III
|
| from Virology Education on Vimeo. Clinical case presentation Christina Mussini, MD University of Modena and Reggio Emilia, Modena, Italy
|
| Oral abstract presentation |
| No videos available for Abstract Presentations |
| from Virology Education on Vimeo. Clinical case presentation Milosz Parczewski, MD, PhD Pomeranian Medical University, Szczecin, Poland
|
| Session IV
|
| One pill a day?: Integration novel delivery systems into routine care (not yet available) Giovanni Di Perri, MD, PhD University of Turin, Turin, Italy |
| from Virology Education on Vimeo. Prospects of immunotherapy for treatment Michael Lederman, MD Case Western Reserve University, Cleveland, Ohio, USA
|